Search

Your search keyword '"Fuchs C.S."' showing total 88 results

Search Constraints

Start Over You searched for: Author "Fuchs C.S." Remove constraint Author: "Fuchs C.S."
88 results on '"Fuchs C.S."'

Search Results

3. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies

4. Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies

5. Nut consumption and risk of colorectal cancer in women

9. Mendelian randomization analysis of n-6 polyunsaturated fatty acid levels and pancreatic cancer risk.

10. Smoking modifies pancreatic cancer risk loci on 2q21.3.

11. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies.

12. Genome-wide association study data reveal genetic susceptibility to chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma risk.

13. Body mass index and Barrett's oesophagus in women

14. Sugar-sweetened beverage and sugar intake during adolescence and risk of colorectal cancer precursors: a large prospective U.S. cohort study

16. 197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859

17. 1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062

18. 1459P Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials

19. KEYNOTE-585 : Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer

20. Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study

21. Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

22. Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062

24. Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer

26. Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer

27. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

28. Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome

29. Habitual intake of flavonoid subclasses and risk of colorectal cancer in 2 large prospective cohorts

30. KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer

31. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials

32. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility

34. LBA44 - Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062

35. 791P - Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

36. Dietary patterns during high school and risk of colorectal adenoma in a cohort of middle-aged women

40. 616PD - Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer

43. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

47. Dietary carotenoids and risk of colorectal cancer in a pooled analysis of 11 cohort studies

48. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies

49. Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas

50. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies

Catalog

Books, media, physical & digital resources